{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:41:41Z","timestamp":1784238101839,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Programmed death\u20101 (PD\u20101) blockade offers a survival advantage over antibody\u2010drug conjugate (ADC) treatment in classic Hodgkin lymphoma (cHL). As such, an updated pharmacoeconomic analysis of these different therapeutic strategies is indicated. This study therefore assessed the cost\u2010effectiveness of nivolumab combined with doxorubicin, vinblastine, and dacarbazine (N\u2010AVD) to that of brentuximab vedotin with AVD (BV\u2010AVD). A three\u2010state Markov model was developed to assess lifetime costs and efficacy for N\u2010AVD and BV\u2010ACVD regimens as treatments for adolescent and adult cHL patients from the perspectives of payers in China and the USA, using respective willingness to pay (WTP) thresholds of $37,608 and $150,000 per quality\u2010adjusted life year (QALY). Primary analytical outcomes included direct medical costs, lifetime efficacy, incremental cost\u2010effectiveness ratio (ICERs), and incremental net health benefit (INHB). Model stability was tested through sensitivity and subgroup analyses. N\u2010AVD treatment yielded 1.41\u20132.01 and 1.06\u20131.39 QALYs over BV\u2010AVD for cHL patients in the USA and China, respectively. Incremental healthcare costs for first\u2010line N\u2010AVD treatment were \u2212$746,249 to $393,009 and \u2212$109,358 to $292,324 compared to BV\u2010AVD treatment, for corresponding ICERs of \u2013$432,098\/QALY to $288,541\/QALY and \u2212$79,173\/QALY to $275,376\/QALY in the USA and China, respectively. Sensitivity analyses suggested that the utility of progression\u2010free survival had an influence on the results of these cost\u2010effectiveness analyses. N\u2010AVD and BV\u2010AVD are cost\u2010effective approaches to treating patients with cHL in both the USA and China. N\u2010AVD and BV\u2010AVD may respectively be best suited to use as treatments for adolescents and elderly individuals.<\/jats:p>","DOI":"10.1002\/hon.70165","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T17:34:41Z","timestamp":1767288881000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["International Cost\u2010Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced\u2010Stage Classic Hodgkin's Lymphoma"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8692-3591","authenticated-orcid":false,"given":"Youwen","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-3310","authenticated-orcid":false,"given":"Kun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-7724","authenticated-orcid":false,"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation Beckman Research Institute City of Hope  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-8070","authenticated-orcid":false,"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-7452","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"Department of Hematology Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)32207\u20108"},{"key":"e_1_2_11_6_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Hodgkin Lymphoma Version 3.2024. Accessed March 18 2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkin_blocks.pdf."},{"key":"e_1_2_11_7_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Pediatric Hodgkin Lymphoma Version 1.2024. Accessed May 14 2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ped_hodgkin.pdf."},{"key":"e_1_2_11_8_1","unstructured":"Guidelines of Chinese Society of Clinical Oncology (CSCO Guidelines): Lymphoma. Accessed April 2024 http:\/\/www.csco.org.cn\/cn\/index.aspx."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206125"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206660"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.4482"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276\u2010018\u20100191\u20101"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2405888"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00122"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2014721"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy193"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561\u2010024\u201000514\u20106"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010021\u201001308\u20108"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7796"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1534738"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016624"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.42400"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002101\u20109"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13522"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.11.014"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102022\u2010068943"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20424"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.7326\/m22\u20102276"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.010"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.985789"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa223"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1103055"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30818"},{"key":"e_1_2_11_37_1","unstructured":"Centers for Medicare & Medicaid Services \u201cDrug Average Sales Price \u201d Accessed October 2 2024 https:\/\/www.cms.gov\/medicare\/payment\/part\u2010b\u2010drugs\/asp\u2010pricing\u2010files."}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:11:55Z","timestamp":1777525915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/hon.70165"],"URL":"https:\/\/doi.org\/10.1002\/hon.70165","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70165"}}